UNASSIGNED: Previous studies concerning the association between @entity117 use and @entity0 risk yielded inconsistent results. We aimed to investigate the association by meta-analysis. PubMed and EMBASE were searched for relevant studies. We calculated the summary relative risks (RR) and 95% confidence intervals (CI) using random-effects models. Seventeen cohort studies and 15 case-control studies were included. The overall result showed that @entity117 use decreased risk of @entity0 (RR, 0.90; 95% CI, 0.85-0.95). However, there was evidence of publication bias and heterogeneity and the association disappeared after correction using the trim-and-fill method. When stratified by study design, a significant benefit for @entity117 users was only found in population-based and hospital-based case-control studies but not in cohort or nest case-control studies. Further subgroup analyses showed that @entity117 use could decrease risk of in situ @entity0 or @entity5282 -positive @entity5 and reduce risk of @entity0 in postmenopausal @entity1 . @entity117 use may not affect overall risk of @entity0 , but decrease risk of in situ @entity0 or @entity5282 -positive @entity5 and reduce risk of @entity0 in postmenopausal @entity1 . Considering between-study significant heterogeneity and publication bias, confirmation in future studies is also essential. Cancer Epidemiol Biomarkers Prev; 24(11); 1-11.   2015 AACR.

XXXX Use and Risk of Breast Cancer: Systematic Review and Meta-analysis of Observational Studies.

@entity1 :: ('9606', 'Species') :: ['women'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin', 'aspirin'] @entity5282 :: ('3164', 'Gene') :: ['hormone receptor']
@entity117 :: (MESH:D001241,Chemical) :: ['Aspirin']
